Anti human cd28 cd28.2

Manufactured by BD

Anti-human CD28 (CD28.2; is a laboratory reagent used for the detection and analysis of CD28, a cell surface receptor on T cells. It is used in flow cytometry and other immunological applications to identify and study T cell populations.

Automatically generated - may contain errors

Lab products found in correlation

Anti human cd3 okt3, by Thermo Fisher Scientific (3 mentions) Rpmi 1640 medium, by Thermo Fisher Scientific (2 mentions) Fetal calf serum (fcs), by PAN Biotech (2 mentions) Formic acid, by Merck Group (2 mentions) Anti human cd3 ucht1, by BD (2 mentions) Anti erk, by Santa Cruz Biotechnology (1 mentions) Anti fas igm antibody, by Merck Group (1 mentions) Phospho plc γ1 tyr783, by Cell Signaling Technology (1 mentions) Phospho zap70 tyr319, by Cell Signaling Technology (1 mentions) Anti phospho lat tyr132, by Abcam (1 mentions) Anti 6 his hrp, by Abcam (1 mentions) Phospho mek ser221, by Cell Signaling Technology (1 mentions) Phospho lat tyr191, by Cell Signaling Technology (1 mentions) Anti grb2, by Abcam (1 mentions) Anti mek, by Cell Signaling Technology (1 mentions) Anti lck, by Santa Cruz Biotechnology (1 mentions) Il 21, by Immunotools (1 mentions) Tgf 1, by R&D Systems (1 mentions) Il 13, by Immunotools (1 mentions) Interleukin 7 (il 7), by Immunotools (1 mentions)

Spelling variants of this product

Anti-CD28 (379 citations) Anti-human CD28 (24 citations) Soluble anti-human CD28 (CD28.2) mAb (4 citations) Soluble anti-human CD28 (28.2) (2 citations)

6 protocols using anti human cd28 cd28.2

T Cell Activation Signaling Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols

The anti-Fas (IgM) antibody, anti-phospho-LAT-Tyr226, and rabbit polyclonal anti-human LAT were from Merck-Millipore; anti-PLC-γ1 mAb, anti-Lck, and anti-Erk were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); antibodies binding phospho-Erk, phospho-PLC-γ1-Tyr783, phospho-ZAP70-Tyr319, phospho-MEK-Ser221, phospho-LAT-Tyr191, and anti-MEK were from Cell Signaling Technology; anti-6His-HRP, anti-Grb2, and anti-phospho-LAT-Tyr132 antibodies were from Abcam (Cambridge, MA, USA); and anti-CD69-APC (allophycocyanin) and anti-β-actin monoclonal antibodies were from Biolegend. The protein synthesis inhibitor cicloheximide was purchased from Merck-Millipore. Stimulations were performed with anti-human CD3 (OKT3; eBioscience) or anti-human CD28 (CD28.2; BD Pharmingen) monoclonal antibodies.

Arbulo-Echevarria M.M., Narbona-Sánchez I., Fernandez-Ponce C.M., Vico-Barranco I., Rueda-Ygueravide M.D., Dustin M.L., Miazek A., Duran-Ruiz M.C., García-Cózar F, & Aguado E. (2018). A Stretch of Negatively Charged Amino Acids of Linker for Activation of T-Cell Adaptor Has a Dual Role in T-Cell Antigen Receptor Intracellular Signaling. Frontiers in Immunology, 9, 115.

+ Open protocol

+ Expand

Cytokine-Induced Differentiation of CD4+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Isolated CD4+ T cells were cultured in RPMI medium 1640 (Gibco) containing 10% FCS (Pan Biotech) and 1% penicillin/streptocmycin (Biochrom) for 3 days in the presence of recombinant interleukin (IL) 6 (20 ng/mL Immunotools), IL-7 (10 ng/mL, Immunotools), IL-9 (10 ng/mL, Immunotools), IL-13 (25 ng/mL, Immunotools), IL-21 (10 ng/mL, Immunotools), IL-33 (10 ng/mL, Biolegend), TGF-ß1 (20 ng/mL, R&D Systems), butyric acid (Roth), propionic acid (Roth), isobutyric acid (abcr), formic acid (Merck) or medium alone. Cells were stimulated with anti-human CD3 (OKT3, eBioscience) and anti-human CD28 (CD28.2, BD Pharmingen) at a final concentration of 1 μg/mL.

Fischer A., Zundler S., Atreya R., Rath T., Voskens C., Hirschmann S., López-Posadas R., Watson A., Becker C., Schuler G., Neufert C., Atreya I, & Neurath M.F. (2015). Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut, 65(10), 1642-1664.

+ Open protocol

+ Expand

Isolation and Expansion of CD4+ Treg Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

We obtained peripheral blood samples from 3 healthy donors and 3 prostate cancer patients. PBMCs were isolated by density gradient centrifugation with Ficoll-Paque (GE Healthcare). Human primary CD4+ CD25-T cells or CD4+ CD25+ Treg cells were purified using the CD4+ T Cell Isolation Kit (Miltenyi Biotec) and CD25 MicroBeads II (Miltenyi Biotec) (Figure S1). CD4+ CD25+ Treg cells were cultured with plate-bound anti-human-CD3 (OKT3; eBiosciences) antibodies (5 μg ml−1) and/or anti-human-CD28 (CD28.2; BD Pharmingen) antibodies (2 μg ml−1) in complete medium [RPMI supplemented with 10% FBS and IL-2 (Peprotech) (100 units ml−1)]. Then, CD4+ CD25+ CD127- Treg cells were enriched using flow cytometry (Figure S1). All cells were cultured at 37°C in an atmosphere of 5% CO2.

Ju M., Fan J., Zou Y., Yu M., Jiang L., Wei Q., Bi J., Hu B., Guan Q., Song X., Dong M., Wang L., Yu L., Wang Y., Kang H., Xin W, & Zhao L. (2022). Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer. Frontiers in Immunology, 13, 807840.

+ Open protocol

+ Expand

T Cell Activation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Unless otherwise stated, T cells were incubated in CM for 24 h before activation. Subsequently, T cells were distributed into 96-well round-bottom plates that were previously coated with 5 ug/ml anti-human CD3 (UCHT1; BD Biosciences, 555329) without changing the culture media. Next, 5 ug/ml anti-human CD28 (CD28.2; BD Biosciences, 555728) was added and cells were maintained for 48 h before downstream analyses were performed.

Érsek B., Silló P., Cakir U., Molnár V., Bencsik A., Mayer B., Mezey E., Kárpáti S., Pós Z, & Németh K. (2020). Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity. Cellular and Molecular Life Sciences, 78(2), 661-673.

+ Open protocol

+ Expand

T Cell Activation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Unless otherwise stated, T cells were incubated in CM for 24 hours before activation. Subsequently, T cells were distributed into 96 well-round bottom plates that were previously coated with 5 ug/ml anti-human CD3 (UCHT1; BD Biosciences, 555329) without changing the culture media. Next, 5 ug/ml anti-human CD28 (CD28.2; BD Biosciences, 555728) was added and cells were maintained for 48h before downstream analyses were performed.

+ Open protocol

+ Expand

Isolation and Stimulation of T Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation with Pancoll (Pan Biotech). CD4 + or CD8 + cells were isolated with immunomagnetic beads (Miltenyi Biotec). Where indicated, cells were cultured in RPMI 1640 medium (Gibco) with 10 % FCS (Pan Biotech) and 1 % penicillin/streptomycin (Biochrom) or X-Vivo medium (Lonza) with 1 % penicillin/streptomycin and stimulated with precoated anti-human CD3 (OKT3, eBioscience) and 1 µg/mL anti-human CD28 (CD28.2, BD) antibodies.
Where indicated, cells were treated with the following recombinant human cytokines for 72 hours: IL-1β, IL-2, IL-4, IL-6, IL-7 (all from Immunotools), IL-9 (Peprotech), IL-12 (all 10 ng/mL), IFN-γ (100 ng/mL, both from Immunotools) and TGF-β (20 ng/mL, R&D Systems). Moreover, cells were treated with CCL-25 (Immunotools), retinoic acid (Cayman Chemical), butyric acid (Roth), isobutyric acid (abcr), formic acid (Merck) and propionic acid (Roth).
For some CCL-25 stimulation experiments, CD4 + CCR9 + and CD8 + CCR9 + cells were purified by FACS (FACS Aria, BD).

Zundler S., Schillinger D., Fischer A., Atreya R., López-Posadas R., Watson A., Neufert C., Atreya I, & Neurath M.F. (2017). Blockade of αEβ7 integrin suppresses accumulation of CD8⁺ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut, 66(11).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!